Thalassemia: a look to the future

Area of Science:

• Medical Sciences
• Genetics
• Hematology

Background:

• Progress in clinical science, particularly in understanding and treating inherited blood disorders, was slow before the molecular biology revolution.
• Early treatments were limited, with blood transfusion being the primary option for conditions like thalassemia and sickle cell disease.

Purpose of the Study:

• To evaluate the historical progression of clinical science over the past century.
• To identify key advancements and areas for future development in managing blood disorders.

Main Methods:

• Historical review of scientific literature and clinical practice from 1925 to 2015.
• Analysis of the impact of the molecular biology revolution on medical advancements.

Main Results:

• Progress was minimal from 1925 to 1964 due to the nascent stage of molecular biology in medicine.
• Significant advancements occurred between 1964 and 2015, including improved understanding of molecular pathophysiology, enhanced transfusion and chelation therapies, stem cell transplantation, gene therapy, and fetal hemoglobin induction.
• Application of prevention technologies in less developed regions has lagged.

Conclusions:

• The molecular biology revolution has dramatically accelerated progress in treating blood disorders.
• Further efforts are needed to implement existing prevention strategies globally, especially for thalassemia and sickle cell disease in underserved populations.